Clinical Trial Update: The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 study comparing oral steroid sulphatase inhibitor BN83495 to Megestrol Acetate in women with advanced or recurrent endometrial cancer completed; results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• BN83495
• Megestrol acetate (megestrol acetate)

Snippet

Sponsor: Ipsen | Conditions: Endometrial Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-09-30